Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Modality
Small molecule
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06841874CT.gov Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Taletrectinib (this asset) | Unk | D · 30 | |
| Carboplatin | Jiangmen Central Hospital | P3 | B |
| Theophylline | NCIC Clinical Trials Group | P3 | B |
| Lumacaftor | Vertex Pharmaceuticals Incorporated | P3 | B |
| Ivacaftor | University of British Columbia | P3 | B |
| Pembrolizumab | Sarah Goldberg | P3 | B |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Jiangmen Central Hospital | P3 | B |
| Buspirone | University of Rochester | P2/3 | CCC |
+42 more in the Lung Disorder cohort
Other indications for Taletrectinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 55 |
| Neoplasm | — | P2 | CCC · 51 |
| Breast Cancer | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Taletrectinib in Lung Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/taletrectinib-lung-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →